Skip to content

AYTU BIOPHARMA, INC.

NASDAQ: AYTU

Company: Aytu BioPharma, Inc.
Ticker: Nasdaq: AYTU
Sector: Healthcare
Investor Contact: Robert Blum

Aytu BioPharma Financials

Financials – Current & Historical

UNAUDITED CONSOLIDATED BALANCE SHEETS
v3.25.0.1
Unaudited Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Jun. 30, 2024
Current assets:    
Cash and cash equivalents $ 20,398 $ 20,006
Accounts receivable, net 25,403 23,526
Inventories 11,085 12,141
Prepaid expenses and other current assets 6,167 5,097
Current assets of discontinued operations 0 1,121
Total current assets 63,053 61,891
Non-current assets:    
Property and equipment, net 516 693
Operating lease right-of-use assets 1,178 829
Intangible assets, net 49,958 52,453
Other non-current assets 1,522 2,185
Non-current assets of discontinued operations 0 44
Total non-current assets 53,174 56,204
Total assets 116,227 118,095
Liabilities, Current [Abstract]    
Accounts payable 11,699 10,314
Accrued liabilities 39,372 38,143
Revolving credit facility 4,012 2,395
Current portion of debt 1,857 1,857
Other Liabilities, Current 7,108 8,962
Current liabilities of discontinued operations 0 557
Total current liabilities 64,048 62,228
Liabilities, Noncurrent [Abstract]    
Debt, net of current portion 9,983 10,877
Derivative warrant liabilities 6,386 12,745
Other Liabilities, Noncurrent 5,045 4,529
Total non-current liabilities 21,414 28,151
Commitments and contingencies (note 13)
Stockholders’ equity:    
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding 0 0
Common stock, par value $.0001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively 1 1
Additional paid-in capital 348,475 347,688
Accumulated deficit (317,711) (319,973)
Total stockholders’ equity 30,765 27,716
Total liabilities and stockholders’ equity $ 116,227 $ 118,095
UNAUDITED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)
v3.25.0.1
Unaudited Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2024
Jun. 30, 2024
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorizzed (in shares) 50,000,000 50,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 200,000,000 200,000,000
Common stock, issued (in shares) 6,169,681 5,972,638
Common stock, outstanding (in shares) 6,169,681 5,972,638
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
v3.25.0.1
Unaudited Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Net revenue $ 16,221 $ 18,748 $ 32,795 $ 36,565
Cost of sales 5,435 4,145 10,024 8,924
Gross profit 10,786 14,603 22,771 27,641
Operating expenses:        
Selling and marketing 5,272 5,218 10,931 11,309
General and administrative 4,449 4,800 9,574 11,095
Research and development 522 521 948 1,116
Amortization of intangible assets 921 918 1,842 1,842
Restructuring costs 1,317 0 2,101 0
Total operating expenses 12,481 11,457 25,396 25,362
(Loss) income from operations (1,695) 3,146 (2,625) 2,279
Other income, net 140 96 682 680
Interest expense (1,079) (1,266) (2,073) (2,549)
Derivative, Gain (Loss) on Derivative, Net 3,016 (577) 5,896 (6,484)
Income (loss) from continuing operations before income tax expense 382 1,399 1,880 (6,074)
Income tax benefit (expense) 283 (780) (122) (780)
Net income (loss) from continuing operations 665 619 1,758 (6,854)
Net income (loss) from discontinued operations, net of tax 123 (839) 504 (1,486)
Net income (loss) $ 788 $ (220) $ 2,262 $ (8,340)
Basic weighted-average common shares outstanding (note 17) (in shares) 6,132,060 5,517,670 6,100,204 5,499,951
Diluted weighted-average common shares outstanding (note 17) (in shares) 8,485,112 5,517,670 8,782,794 5,499,951
Net income (loss) per share (note 17):        
Basic - continuing operations (in dollars per share) $ 0.11 $ 0.11 $ 0.29 $ (1.25)
Diluted - continuing operations (in dollars per share) (0.28) 0.11 (0.47) (1.25)
Basic - discontinued operations, net of tax (in dollars per share) 0.02 (0.15) 0.08 (0.27)
Diluted - discontinued operations, net of tax (in dollars per share) 0.01 (0.15) 0.06 (0.27)
Basic - net income (loss) (in dollars per share) 0.13 (0.04) 0.37 (1.52)
Diluted - net loss (in dollars per share) $ (0.26) $ (0.04) $ (0.41) $ (1.52)
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
v3.25.0.1
Unaudited Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net income (loss) $ 2,262 $ (8,340)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:    
Depreciation, amortization and accretion 2,766 3,634
Stock-based compensation expense 324 1,432
Derivative warrant liabilities (gain) loss (5,896) 6,484
Amortization of debt discount and issuance costs 55 302
Inventory write-down 95 51
Other non-cash adjustments (529) (50)
Non-cash adjustments from discontinued operations 254 1,176
Changes in operating assets and liabilities:    
Accounts receivable, net (1,794) (1,566)
Inventories 961 (1,805)
Prepaid expenses and other current assets (679) (830)
Accounts payable 1,329 (3,062)
Accrued liabilities 2,341 (3,554)
Other operating assets and liabilities, net 306 3,805
Changes in operating assets and liabilities from discontinued operations (80) 1,977
Net cash provided by (used in) operating activities 1,715 (346)
Cash flows from investing activities:    
Cash received from sales of fixed assets 668 0
Cash payments for fixed asset purchases (142) 0
Other investing activities 0 (250)
Net cash provided by (used in) investing activities 526 (250)
Cash flows from financing activities:    
Proceeds from issuance of stock and warrants 0 86
Net proceeds received from (payments made on) revolving credit facility 1,617 (537)
Payment made to fixed payment arrangements (2,537) (2,204)
Payment of stock issuance costs 0 (160)
Payments made to borrowings (929) (45)
Net cash used in financing activities (1,849) (2,860)
Net change in cash and cash equivalents 392 (3,456)
Cash and cash equivalents at beginning of period 20,006 22,985
Cash and cash equivalents at end of period 20,398 19,529
Supplemental disclosure of cash flow information:    
Cash paid for interest 752 2,170
Cash paid for income taxes 1,419 432
Non-cash investing and financing activities:    
Other non-cash investing and financing activities $ 483 $ 0

Arrow